soul trial oral semaglutide cardiovascular outcomes 2024 results nejm SOUL: Bests Usual Care in High-Risk Type 2 Diabetes VisualAbstract: Semaglutide Improves Outcomes in

Not everyone responds to tirzepatide in the same way

Research published in the New England Journal of Medicine found that participants using semaglutide achieved an average weight reduction of nearly 15% of their body weight, substantially outperforming traditional lifestyle interventions alone

UK outlook for GLP-1 Diabetes Treatment Drugs Market Revenue from GLP-1 diabetes treatment drugs in the United Kingdom is projected to grow at a CAGR of 21.5% through 2035, supported by the country's healthcare system development, advanced diabetes care capabilities, and established expertise in pharmaceutical solutions

We recognize that navigating this process can feel overwhelming, and thats why this guide emphasizes the importance of accurate dosing to maximize the benefits of semaglutide while minimizing potential side effects